Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond

Journal of Medicinal Chemistry

Volumn 47, Issue 13, 2004, Pages 3418-3426

  Velázquez, Sonsoles ^a   Lobatón, Esther ^a   De Clercq, Erik ^b   Koontz, Dianna L ^c   Mellors, John W ^c   Balzarini, Jan ^b   Camarasa, María José ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE)NUCLEOSIDE DERIVATIVE; ESTER; FOSCARNET DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DESIGN; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYBRID; VIRUS INHIBITION;

CELL EXTRACTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; DRUG STABILITY; FOSCARNET; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; HYDROLYSIS; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 2942602682     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031045o     Document Type: Article

References (34)

1. (a) De Clercq, E. New developments in anti-HIV chemotherapy. Biochem. Biophys. Acta 2002, 258-275.
2. (b) De Clercq, E. Antiviral drugs: current state of the art. J. Clin. Virol. 2001, 22, 73-89.
3. Balzarini, J. Suppresion of resistance to drugs targeted to Human Inmunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. 1999, 58, 1-27.
4. Tavel, J. A.; Miller, K. D.; Masur, H. Guide to major clinical trials of antiretroviral therapy in human inmunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors. Clin. Infect. Dis. 1999, 28, 643-676.
5. (a) Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Morelli, E.; Novellino, E. Non-nucleoside HIV-1 Reverse Transcriptase (RT) inhibitors: Past, Present and Future perspectives. Current Pharmaceutical Design 2002, 8, 615-657.
6. (b) De Clercq, E. The role of non-nucleoside reverse transcripatse inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
7. (a) Balzarini, J.; Pérez-Pérez, M. J.; San-Félix, A.; Schols, D.; Perno, C. F.; Vandamme, A. M.; Camarasa, M. J.; De Clercq, E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. USA 1992, 89, 4392-4396.
8. (b) Camarasa, M. J.; Pérez-Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3′-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of 3′-spiro-5″-[4″ -amino-1″,2″-oxathiole-2″,2″-dioxide] pyrimidine nucleosides. J. Med. Chem. 1992, 35, 2721-2727.
9. Camarasa, M. J.; San-Félix, A.; Pérez-Pérez, M. J.; Velázquez, S.; Alvarez, R.; Chamorro, C.; Jimeno, M. L.; Pérez, C.; Gago, F.; De Clercq, E.; Balzarini, J. HIV-1 specific reverse transcriptase inhibitors: why are TSAO-nucleosides so unique?. J. Carbohydr. Chem. 2000, 19, 451-469.
10. Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Pérez-Pé rez, M. J.; Camarasa, M. J.; Pelemans, H.; Balzarini, J.; Gago, F. Identification of a putative binding site for [2′,5′ -Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 Reverse Transcriptase. J. Med. Chem. 2001, 44, 1853-1865.
11. Harris, D.; Lee, R.; Misra, H. S.; Pandey, P. K.; Pandey, V. N. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998, 37, 5903-5908.
12. Sluis-Cremer, N.; Dmitrienko, G. I.; Balzarini, J.; Camarasa, M. J.; Parniak, M. A. Human Immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-{spiro-[4″-amino-2″,2″-dioxo-1″ ,2″-oxathiole-5″,3′-[2′,5′ -bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]]}-3-ethylthymine. Biochemistry 2000, 39, 1427-1433.
13. (a) Balzarini, J.; Kleim, J. P.; Riess, G.; Camarasa, M. J.; De Clercq, E.; Karlsson, A. Sensitivity of (138 GLU→LYS) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 1994, 201, 1305-1312.
14. 138→Lys on the p51 subunit. J. Biol. Chem. 1994, 269, 25255-25258.
15. (a) Oberg, B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmac. Ther. 1989, 40, 213-285.
16. (b) Wagstaff, A. J.; Bryson, H. M. Foscarnet. Drugs 1994, 48, 199-226.
17. (c) Chrisp, P.; Clissold, S. F. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in inmunocompromised patients with cytomegaloviruses retinitis. Drugs 1991, 41, 104-129.
18. Fletcher, C. V.; Collier, A. C.; Rhame, F. S.; Bennet, D.; Para, M. F.; Beatty, C. C.; Jones, C. E.; Balfour, H. H.; Jr. Foscarnet for suppresion of human immunodeficiency virus replication. Antimicrob. Agents Chemother. 1994, 38, 604-607.
19. Noormohamed, F. H.; Youls, M. S.; Higgs, C. J.; Martin, M.; Gazzard, B. G.; Lant, A. F. Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients. Antimicrob. Agents Chemother. 1998, 42, 293-297.
20. (a) Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.-J.; Camarasa, M.-J.; Tarpley, W. G.; De Clercq, E. Treatment of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells with Combinations of HIV-1-Specific Inhibitors Results in a Different Resistance Pattern than does treatment with Single-Drug Therapy. J. Virol. 1993, 67, 5353-5359.
21. (b) Balzarini, J.; Pelemans, H.; Karlsson, A.; De Clercq, E.; Kleim, J.-P. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 1996, 93, 13152-13157.
22. Balzarini, J.; Pelemans, H.; Pérez-Pérez, M.-J.; San-Félix, A.; Camarasa, M.-J.; De Clercq, E.; Karlsson, A. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)-2′, 3′-dideoxy-3′-thiacytidine. Mol. Pharm. 1996, 49, 882-890.
23. (a) Vaghefi, M.; McKernan, P.; Robins, R. Synthesis and antiviral activity of certain nucleoside 5′-phosphonoformate derivatives. J. Med. Chem. 1986, 29, 1389-1393.
24. (b) Griengl, H.; Hayden, W.; Penn, G.; De Clercq, E.; Rosewirth, B. Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2′-deoxyuridines: synthesis and antiviral activity. J. Med. Chem. 1988, 31, 1831-1839.
25. (a) Rosowsky, A.; Saha, J.; Fazeli, F.; Koch, J.; Ruprecht, R. Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate esters of 3′-azido-3′-deoxythymidine. Biochem. Biophys. Res. Commun. 1990, 172, 288-294.
26. (b) Saha, H.; Ruprecht, R. M.; Rosowsky, A. Phosphonoformate esters of anti-HIV nucleosides: 3′-azido-3′-deoxythymidine and 2′,3′-dideoxycytidine derivatives containing a small 5′-O-(alkoxycarbonylphosphinyl) or 5′ -O-(cholesterylcarbonylphosphinyl)substituent. Nucleosides Nucleotides 1991, 10, 1465-1475.
27. (a) Charvet, A.-S.; Camplo, M.; Faury, P.; Graciet, J.-C.; Mourier, N.; Chermann, J.-C.; Kraus, J.-L. Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2′,3′ -dideoxy-3′-thiacytidine. J. Med. Chem. 1994, 37, 2216-2223.
28. (b) Rosowsky, A.; Hongning, F.; Pai, N.; Mellors, J.; Richman, D. D.; Hostetler, K. Y. Synthesis and in vitro activity of long-chain 5′-O-[alkoxycarbonyl)phosphinyl]-3′-azido-3′-deoxythymidines against wild-type and AZT- and Foscarnet-resistant strains of HIV-1. J. Med. Chem. 1997, 40, 2482-2490.
29. Meier, C.; Aubertin, A.-M.; de Monte, M.; Faraj, A.; Sommadossi, J.-P.; Périgaud, C.; Imbach, J.-L.; Gosselin, G. Synthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates. Antiviral Chem. Chemother. 1998, 9, 41-51.
30. Noren, J. A.; Helgstrand, E.; Johansson, N. G.; Misiorny, A.; Stening, G. Synthesis of esters of phosphonoformic acid and their antiherpes activity. J. Med. Chem. 1983, 26, 264-270.
31. (a) Krol, E. S.; Davis, J. M.; Thatcher, G. R. J. Hydrolisis of phosphonoformate esters: product distribution and reactivity patterns. J. Chem. Soc., Chem. Commun. 1991, 118-119.
32. (b) Mitchell, A. G.; Nichols, D.; Irwin, W. J.; Freeman, S. J. Chem. Soc., Perkin Trans. 2 1992, 1145-1150.
33. Log P was calculated using the algorithm available at www.log-p.com. This interactive prediction analysis used E-state atom indices with neural network algorithms.
34. Balzarini, J.; Kleim, J.-P.; Riess, G.; Camarasa, M.-J.; De Clercq, E., Karlsson, A. Sensitivity of (138 Glu → Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 1994, 201, 1305-1312.